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Retropubic radical prostatectomy (RRP) is one of the
most important treatment modalities for localized pros-
tate cancer. The procedure is well known to be cause
severe bleeding; even experienced surgeons have re-
ported a blood transfusion rate of up to 20% [1–5]. The
neurovascular bundle should be preserved for po-
tency and continence and this preservation means that
coagulation or hemostasis techniques should be main-
tained at a minimum level. In other words, during
RRP, routine hemostatic techniques (mono or bipolar
cautery, metal clips or bipolar open forceps, for exam-
ple) should be the first choice to manage bleeding.
Ankaferd BloodStopper® (ABS) is a unique medici-
nal plant extract, which has historically been used in
Turkish traditional medicine. This product includes
five plants and each of them has some effects on the
endothelium, blood cells, angiogenesis, cellular pro-
liferation, vascular dynamics and cell mediators [6].
Furthermore, the efficacy of ABS in open heart surgery
and upper gastrointestinal bleeding have also been
confirmed [7,8]. In this case report, we evaluated the
antihemostatic effect of local ABS application in a
male patient who underwent RRP.
CASE PRESENTATION
A 66-year-old man was admitted to our outpatient
clinic complaining of lower urinary tract symptoms.
Disease-specific history, physical examination, blood
and urine analysis, prostate specific antigen (PSA),
digital rectal examination and uroflowmetry were per-
formed. The total PSA level was 15.9 ng/mL. Patho-
logic examination of a transrectal ultrasound-guided
biopsy specimen revealed prostate adenocarcinoma
(Gleason Score: 3 + 4 = 7) in the right lobe. Retropubic
radical prostatectomy was planned. We aimed to in-
vestigate the effect of ABS as a hemostatic agent dur-
ing the RRP. Therefore, the patient signed the informed
consent form authorizing us to use ABS during RRP.
Routine electrocautery, metal clips and open bipolar
plasmakinetic forceps were available for hemostasis.
ABS tampons sized 2.5 × 7 cm were used to provide
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hemostasis. ABS was applied for hemorrhages that
could not being managed with conventional proce-
dures. The application regions did not include the
dorsal venous complex, the neurovascular bundle 
or the urethra, and the application method involved
compressing the ABS tampon onto the bleeding region
for at least 2 minutes (Figure 1). Because the ABS
tampons are non-absorbable products, we had to
remove the tampon when the bleeding had stopped.
The operation time was nearly 210 minutes. The
amount of blood loss was 500mL and one unit of blood
was transfused to the patient. No serious complica-
tion was observed. During this RRP, the hemostatic
control was only provided at the posterior plane of
the prostate and the Denonvillier fascia after the for-
mation of an ABS aggregate (red area) (Figure 2). We
observed that a well-compressed tampon was suffi-
cient to obtain hemostasis.
DISCUSSION
ABS comprises a standardized mixture of the plants
Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia
officinarum and Urtica dioica. This product has been 
licensed for use for external, dental and postsurgical
major or minor hemorrhages. It has been confirmed
that ABS does not have any limitation for its use. The
basic mechanism of ABS in the hemostatic process is
the formation of an encapsulated protein network that
provides focal points for vital erythrocyte aggregation.
The protein network induced by ABS is formed rap-
idly (< 1 second); however, blood cells, particularly
erythrocytes, participate in protein network forma-
tion [6]. ABS is produced by a registered Turkish com-
pany. In Turkey, some studies have been performed
to investigate the efficacy of ABS in stopping bleed-
ing in visceral organs; however, this is the first clinical
application of ABS in a urology clinic to evaluate its
antihemostatic effect during RRP.
It has been shown that a combination of factors
such as intraoperative fluid reduction, epidural cathe-
ter usage and Trendelenburg positioning significantly
decreased blood loss and transfusion [9].
Zelster et al confirmed that the use of a topical
hemostatic agent along the neurovascular bundle in
dogs did not adversely affect cavernous nerve func-
tion, measured as the erectile response to electrical
stimulation [10]. An ideal topical hemostatic agent
for use in surgical procedures, such as radical prosta-
tectomy, should be easy to use, exert its effects within
minutes and be effective against arterial and venous
bleeding. Furthermore, it should not damage the
neurovascular bundle or urethra, and not be toxic or
anaphylactic. In this case, hemostasis during RRP was
provided by applying ABS onto tissues with active
hemorrhages. Here, we observed the clinical efficacy
of ABS during RRP.
The aim of this case report was to investigate the
hemostatic efficacy of ABS, which is a novel Turkish
topical hemostatic agent, during RRP. According to
our observations, ABS has a major effect on providing
active hemostasis during RRP. In our opinion, further
clinical studies with large numbers may support our
findings and show the hemostatic efficacy of ABS in
surgical procedures, including RRP.
Figure 2. Compressive use of Ankaferd BloodStopper® during
open surgery completely controlled the bleeding within 2 minutes.
Figure 1. Active bleeding on posterior plane of the prostate 
during radical prostatectomy and application of an Ankaferd
BloodStopper® tampon onto the bleeding area.
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